Key result
Rivaroxaban was associated with a 23% reduced hazard of postthrombotic syndrome compared to warfarin in patients with venous thromboembolism (HR 0.77; 95% CI 0.70-0.84).
Why the study?
Does rivaroxaban reduce the risk of postthrombotic syndrome compared to warfarin in adults treated for venous thromboembolism?
Population
36,957 adults with a primary diagnosis of venous thromboembolism during a hospitalization or emergency…
Comparison
Rivaroxaban vs Warfarin
Design
Cohort
Follow-up
mean 16 ± 9 months (range, 4-39 months)
Authors
Loading...
Rivaroxaban was associated with lower PTS risk after VTE; leaves open whether it should replace warfarin pending randomized confirmation.
Cohort (n=36,957)
Does rivaroxaban reduce the risk of postthrombotic syndrome compared to warfarin in adults treated for venous thromboembolism?
Hazard Ratio: 0.77 (95% CI 0.7–0.84)
In routine clinical practice, treating venous thromboembolism with rivaroxaban is associated with a significantly lower risk of developing postthrombotic syndrome compared to warfarin.
Coleman et al. (2018) conducted a cohort in Venous thromboembolism (VTE) (n=36,957). Rivaroxaban vs. Warfarin was evaluated on Development of postthrombotic syndrome (PTS) (HR 0.77, 95% CI 0.70-0.84). Rivaroxaban was associated with a 23% reduced hazard of postthrombotic syndrome compared to warfarin in patients with venous thromboembolism (HR 0.77; 95% CI 0.70-0.84).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: